A Personalized Approach to Asthma Management:
The New Asthma Treatment Guidelines
Release date: January 2008
Expiration date: December 31, 2008
Estimated time to complete activity: 2.0 hours
Target Audience
This activity has been designed to meet the educational needs of allergists, pulmonologists, and primary care physicians involved in the care of patients with asthma.
Statement of Need/Program Overview
Recently, the National Asthma Education and Prevention Program guidelines were released. One of the advances in asthma management is an added emphasis on risk assessment and monitoring the patient’s response to pharmacotherapy. The new guidelines also make recommendations with regard to single-entity inhaled corticosteroid (ICS) therapy in the management of asthma. This educational activity will review the evolving asthma marketplace and the updated role of ICSs in asthma management.
Educational Objectives
After completing this activity, the participant should be better able to:
- Review the latest asthma treatment guidelines in clinical practice
- Identify the risk of asthma exacerbations in patients with mild-to-moderate persistent asthma
- Explain the importance of continual assessment of response to therapy for patients with persistent asthma
- Specify the primacy of ICS in treating patients with mild-to-moderate persistent asthma
- Recall the recommendations regarding the use of combination therapy (ICS-LABA) in mild, moderate, and severe persistent asthma
Faculty
Gene L. Colice, MD
Professor of Medicine,
George Washington University
School of Medicine,
Washington, DC
Director, Pulmonary, Critical Care and
Respiratory Services,
Washington Hospital Center,
Washington, DC
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Integrity Continuing Education. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Gene L. Colice, MD
Honoraria: Adams Laboratories, ALTANA Pharma US., Inc (a division of NYCOMED), sanofi-aventis
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Steven A. Henry, MD No real or apparent conflicts of interest to report
Linda Graham, RN, MSN No real or apparent conflicts of interest to report
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period January 2008 through December 31, 2008, participants must:
- Read the learning objectives and faculty disclosures
- Study the educational activity
- Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
- Complete the evaluation form
- Mail or fax the evaluation form with answer key to PIM.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Integrity Continuing Education, and TEVA Specialty Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Integrity Continuing Education, or TEVA Specialty Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
